Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GNFT
stocks logo

GNFT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast GNFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNFT is 7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast GNFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNFT is 7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.850
sliders
Low
7.00
Averages
7.50
High
8.00
Current: 4.850
sliders
Low
7.00
Averages
7.50
High
8.00
H.C. Wainwright
Buy
downgrade
$9 -> $7
2025-09-24
Reason
H.C. Wainwright
Price Target
$9 -> $7
2025-09-24
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Genfit to $7 from $9 and keeps a Buy rating on the shares. The company last week announced the discontinuation of VS-01 in acute on chronic liver failure following a case of peritonitis in the UNVEIL-IT study, the analyst tells investors in a research note. The firm updated Genfit's model for the discontinuation and the company's half year earnings report.
H.C. Wainwright
H.C. Wainwright
initiated
$9
2025-08-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$9
2025-08-19
initiated
Reason
H.C. Wainwright assumed coverage of Genfit with a Buy rating and $9 price target. The company is developing therapies for rare and severe liver diseases, with a focus on acute-on-chronic liver failure, the analyst tells investors in a research note. The firm says the company is expected to readout multiple meaningful clinical updates in 2025 and beyond, providing a number of catalysts for the shares.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$13
2025-02-07
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$13
2025-02-07
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Genfit SA (GNFT.O) is -20.78, compared to its 5-year average forward P/E of 5.38. For a more detailed relative valuation and DCF analysis to assess Genfit SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
5.38
Current PE
-20.78
Overvalued PE
55.57
Undervalued PE
-44.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
1.24
Current EV/EBITDA
-13.03
Overvalued EV/EBITDA
14.93
Undervalued EV/EBITDA
-12.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.12
Current PS
3.06
Overvalued PS
9.82
Undervalued PS
0.41
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

GNFT News & Events

Events Timeline

(ET)
2025-10-30
17:05:23
Genfit Plans to Delist ADSs from Nasdaq Voluntarily
select
2025-05-20 (ET)
2025-05-20
16:17:40
Genfit to receive EUR 26.5M Iqirvo milestone payment from Ipsen agreement
select
2025-02-10 (ET)
2025-02-10
04:25:41
Genfit announces final terms for dual proposal to 2025 Oceanes holders
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-28NASDAQ.COM
Genfit Names Pejvack Motlagh as Chief Medical Officer

  • Appointment Announcement: Genfit has appointed Pejvack Motlagh as its new Chief Medical Officer.

  • Professional Background: Motlagh brings over 20 years of experience in the pharmaceutical and biotechnology sectors, having previously served as CMO at Egle Therapeutics and Mablink Biosciences.

[object Object]
Preview
5.0
11-28Globenewswire
GENFIT Appoints New CMO to Drive Clinical Development Strategy
  • New Chief Medical Officer: GENFIT announces the appointment of Dr. Pejvack Motlagh as the new Chief Medical Officer, who will oversee the company's clinical development strategy and execution, expected to enhance the company's R&D capabilities in liver diseases.
  • Extensive Industry Experience: Dr. Motlagh brings over 20 years of experience in the pharmaceutical and biotechnology sectors, having served as CMO at several large pharmaceutical and innovative biotech firms, which will provide deep expertise to GENFIT's clinical programs.
  • Focus on Liver Disease Treatment: At a pivotal moment when Acute on-Chronic Liver Failure is gaining attention in the liver disease community, Dr. Motlagh's leadership is anticipated to drive GENFIT's innovation and patient-centric development, addressing high unmet medical needs.
  • CEO's Expectations: GENFIT's CEO Pascal Prigent stated that Dr. Motlagh's leadership will be crucial for advancing the pipeline and fulfilling the mission to deliver transformative therapies, reflecting the company's confidence in future growth.
[object Object]
Preview
4.5
09-22Benzinga
Dow Reaches All-Time High Following Fed Rate Cuts: Investor Confidence Rises, Fear Index Stays in 'Greed' Territory

  • Market Sentiment: The CNN Money Fear and Greed index improved to 62.1, indicating a sentiment in the "Greed" zone, while U.S. stocks, including the Dow Jones and S&P 500, closed higher with significant gains last week.

  • Apple's Performance: Apple Inc. saw a 3.2% increase in stock value due to strong demand for the new iPhone 17, with preorders surpassing those of the iPhone 16 in just one minute, pushing shares above $245.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Genfit SA (GNFT) stock price today?

The current price of GNFT is 4.85 USD — it has increased 2.47 % in the last trading day.

arrow icon

What is Genfit SA (GNFT)'s business?

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

arrow icon

What is the price predicton of GNFT Stock?

Wall Street analysts forecast GNFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNFT is 7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Genfit SA (GNFT)'s revenue for the last quarter?

Genfit SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

arrow icon

What is Genfit SA (GNFT)'s earnings per share (EPS) for the last quarter?

Genfit SA. EPS for the last quarter amounts to USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Genfit SA (GNFT)'s fundamentals?

The market is revising Downward the revenue expectations for Genfit S.A. (GNFT) for FY2025, with the revenue forecasts being adjusted by -24.08% over the past three months. During the same period, the stock price has changed by 23.10%.
arrow icon

How many employees does Genfit SA (GNFT). have?

Genfit SA (GNFT) has 180 emplpoyees as of December 06 2025.

arrow icon

What is Genfit SA (GNFT) market cap?

Today GNFT has the market capitalization of 192.46M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free